Canaccord analyst Dewy Steadman raised his price target on Insmed to $32 from $20 following its “blowout” preannouncement last week. The analyst is cautiously optimistic about 2019 performance as even a rock-bottom base revenue assumption is above consensus revenue. He also believes Arikayce will become core to the NTM treatment paradigm over time, making current valuation an attractive entry points for investors. Steadman reiterated his Buy rating on Insmed shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.